166 related articles for article (PubMed ID: 37604268)
1. Progression of non-alcoholic fatty liver disease and long-term outcomes: A nationwide paired liver biopsy cohort study.
Simon TG; Roelstraete B; Hagström H; Loomba R; Ludvigsson JF
J Hepatol; 2023 Dec; 79(6):1366-1373. PubMed ID: 37604268
[TBL] [Abstract][Full Text] [Related]
2. Mortality in biopsy-confirmed nonalcoholic fatty liver disease: results from a nationwide cohort.
Simon TG; Roelstraete B; Khalili H; Hagström H; Ludvigsson JF
Gut; 2021 Jul; 70(7):1375-1382. PubMed ID: 33037056
[TBL] [Abstract][Full Text] [Related]
3. Non-alcoholic fatty liver disease and incident major adverse cardiovascular events: results from a nationwide histology cohort.
Simon TG; Roelstraete B; Hagström H; Sundström J; Ludvigsson JF
Gut; 2022 Sep; 71(9):1867-1875. PubMed ID: 34489307
[TBL] [Abstract][Full Text] [Related]
4. Non-alcoholic fatty liver disease in children and young adults is associated with increased long-term mortality.
Simon TG; Roelstraete B; Hartjes K; Shah U; Khalili H; Arnell H; Ludvigsson JF
J Hepatol; 2021 Nov; 75(5):1034-1041. PubMed ID: 34224779
[TBL] [Abstract][Full Text] [Related]
5. Familial coaggregation of MASLD with hepatocellular carcinoma and adverse liver outcomes: Nationwide multigenerational cohort study.
Ebrahimi F; Hagström H; Sun J; Bergman D; Shang Y; Yang W; Roelstraete B; Ludvigsson JF
J Hepatol; 2023 Dec; 79(6):1374-1384. PubMed ID: 37647992
[TBL] [Abstract][Full Text] [Related]
6. Cardiovascular disease risk in paediatric and young adult non-alcoholic fatty liver disease.
Simon TG; Roelstraete B; Alkhouri N; Hagström H; Sundström J; Ludvigsson JF
Gut; 2023 Mar; 72(3):573-580. PubMed ID: 36522149
[TBL] [Abstract][Full Text] [Related]
7. Cancer Risk in Patients With Biopsy-Confirmed Nonalcoholic Fatty Liver Disease: A Population-Based Cohort Study.
Simon TG; Roelstraete B; Sharma R; Khalili H; Hagström H; Ludvigsson JF
Hepatology; 2021 Nov; 74(5):2410-2423. PubMed ID: 33811766
[TBL] [Abstract][Full Text] [Related]
8. Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD.
Hagström H; Nasr P; Ekstedt M; Hammar U; Stål P; Hultcrantz R; Kechagias S
J Hepatol; 2017 Dec; 67(6):1265-1273. PubMed ID: 28803953
[TBL] [Abstract][Full Text] [Related]
9. Association of Bariatric Surgery With Major Adverse Liver and Cardiovascular Outcomes in Patients With Biopsy-Proven Nonalcoholic Steatohepatitis.
Aminian A; Al-Kurd A; Wilson R; Bena J; Fayazzadeh H; Singh T; Albaugh VL; Shariff FU; Rodriguez NA; Jin J; Brethauer SA; Dasarathy S; Alkhouri N; Schauer PR; McCullough AJ; Nissen SE
JAMA; 2021 Nov; 326(20):2031-2042. PubMed ID: 34762106
[TBL] [Abstract][Full Text] [Related]
10. Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management.
McPherson S; Hardy T; Henderson E; Burt AD; Day CP; Anstee QM
J Hepatol; 2015 May; 62(5):1148-55. PubMed ID: 25477264
[TBL] [Abstract][Full Text] [Related]
11. Risk of Severe Infection in Patients With Biopsy-proven Nonalcoholic Fatty Liver Disease - A Population-based Cohort Study.
Ebrahimi F; Simon TG; Hagström H; Söderling J; Wester A; Roelstraete B; Ludvigsson JF
Clin Gastroenterol Hepatol; 2023 Dec; 21(13):3346-3355.e19. PubMed ID: 37245712
[TBL] [Abstract][Full Text] [Related]
12. Fibrosis Severity as a Determinant of Cause-Specific Mortality in Patients With Advanced Nonalcoholic Fatty Liver Disease: A Multi-National Cohort Study.
Vilar-Gomez E; Calzadilla-Bertot L; Wai-Sun Wong V; Castellanos M; Aller-de la Fuente R; Metwally M; Eslam M; Gonzalez-Fabian L; Alvarez-Quiñones Sanz M; Conde-Martin AF; De Boer B; McLeod D; Hung Chan AW; Chalasani N; George J; Adams LA; Romero-Gomez M
Gastroenterology; 2018 Aug; 155(2):443-457.e17. PubMed ID: 29733831
[TBL] [Abstract][Full Text] [Related]
13. Long-term major adverse liver outcomes in 1,260 patients with non-cirrhotic NAFLD.
Akbari C; Dodd M; Stål P; Nasr P; Ekstedt M; Kechagias S; Vessby J; Rorsman F; Zhang X; Wang T; Jemielita T; Fernandes G; Engel SS; Hagström H; Shang Y
JHEP Rep; 2024 Feb; 6(2):100915. PubMed ID: 38293684
[TBL] [Abstract][Full Text] [Related]
14. Association of Histologic Disease Activity With Progression of Nonalcoholic Fatty Liver Disease.
Kleiner DE; Brunt EM; Wilson LA; Behling C; Guy C; Contos M; Cummings O; Yeh M; Gill R; Chalasani N; Neuschwander-Tetri BA; Diehl AM; Dasarathy S; Terrault N; Kowdley K; Loomba R; Belt P; Tonascia J; Lavine JE; Sanyal AJ;
JAMA Netw Open; 2019 Oct; 2(10):e1912565. PubMed ID: 31584681
[TBL] [Abstract][Full Text] [Related]
15. Clinical validation of the FLIP algorithm and the SAF score in patients with non-alcoholic fatty liver disease.
Nascimbeni F; Bedossa P; Fedchuk L; Pais R; Charlotte F; Lebray P; Poynard T; Ratziu V;
J Hepatol; 2020 May; 72(5):828-838. PubMed ID: 31862486
[TBL] [Abstract][Full Text] [Related]
16. Non-alcoholic fatty liver disease - histological scoring systems: a large cohort single-center, evaluation study.
Rastogi A; Shasthry SM; Agarwal A; Bihari C; Jain P; Jindal A; Sarin S
APMIS; 2017 Nov; 125(11):962-973. PubMed ID: 29076589
[TBL] [Abstract][Full Text] [Related]
17. Defining the serum proteomic signature of hepatic steatosis, inflammation, ballooning and fibrosis in non-alcoholic fatty liver disease.
Sanyal AJ; Williams SA; Lavine JE; Neuschwander-Tetri BA; Alexander L; Ostroff R; Biegel H; Kowdley KV; Chalasani N; Dasarathy S; Diehl AM; Loomba R; Hameed B; Behling C; Kleiner DE; Karpen SJ; Williams J; Jia Y; Yates KP; Tonascia J
J Hepatol; 2023 Apr; 78(4):693-703. PubMed ID: 36528237
[TBL] [Abstract][Full Text] [Related]
18. Inevitability of disease recurrence after liver transplantation for NAFLD cirrhosis.
Villeret F; Dharancy S; Erard D; Abergel A; Barbier L; Besch C; Boillot O; Boudjema K; Coilly A; Conti F; Corpechot C; Duvoux C; Faitot F; Faure S; Francoz C; Giostra E; Gugenheim J; Hardwigsen J; Hilleret MN; Hiriart JB; Houssel-Debry P; Kamar N; Lassailly G; Latournerie M; Pageaux GP; Samuel D; Vanlemmens C; Saliba F; Dumortier J
JHEP Rep; 2023 Mar; 5(3):100668. PubMed ID: 36852108
[TBL] [Abstract][Full Text] [Related]
19. Advanced fibrosis is associated with incident cardiovascular disease in patients with non-alcoholic fatty liver disease.
Henson JB; Simon TG; Kaplan A; Osganian S; Masia R; Corey KE
Aliment Pharmacol Ther; 2020 Apr; 51(7):728-736. PubMed ID: 32043602
[TBL] [Abstract][Full Text] [Related]
20. Daily Aspirin Use Associated With Reduced Risk For Fibrosis Progression In Patients With Nonalcoholic Fatty Liver Disease.
Simon TG; Henson J; Osganian S; Masia R; Chan AT; Chung RT; Corey KE
Clin Gastroenterol Hepatol; 2019 Dec; 17(13):2776-2784.e4. PubMed ID: 31077838
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]